Uncategorized

Calliditas announces supportive interim data from Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib

Calliditas Therapeutics AB announced interim data from the proof-of-concept Phase 2 trial in patients with squamous cell carcinoma of the head and neck with its lead NOX 1 and 4 inhibitor product candidate, setanaxib.

Calliditas announces supportive interim data from Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib Read More »

Bicycle Therapeutics Announces Pricing of $200 Million Public Offering of American Depositary Shares and Non-Voting Ordinary Shares

Bicycle Therapeutics plc announced the pricing of an underwritten public offering of 9,411,766 American Depositary Shares, each representing one ordinary share and, in lieu of ADSs to investors that so choose, non-voting ordinary shares, each at a price to the public of $21.25 per share, for gross proceeds of approximately $200.0 million.

Bicycle Therapeutics Announces Pricing of $200 Million Public Offering of American Depositary Shares and Non-Voting Ordinary Shares Read More »

Positive Results Announced from Phase 3 OCARINA II Trial Evaluating Roche’s OCREVUS® (ocrelizumab) with Halozyme’s ENHANZE® Drug Delivery Technology in Patients with Multiple Sclerosis

Halozyme Therapeutics, Inc. announced that Roche’s Phase 3 OCARINA II trial evaluating OCREVUS® with ENHANZE® as a twice a year 10-minute subcutaneous injection, met its primary and secondary endpoints in patients with relapsing forms of multiple sclerosis or primary progressive MS.

Positive Results Announced from Phase 3 OCARINA II Trial Evaluating Roche’s OCREVUS® (ocrelizumab) with Halozyme’s ENHANZE® Drug Delivery Technology in Patients with Multiple Sclerosis Read More »

Scroll to Top